DOM-SUMATRIPTAN TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
22-08-2016
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
SUMATRIPTAN (SUMATRIPTAN SUCCINATE)
Fáanlegur frá:
DOMINION PHARMACAL
ATC númer:
N02CC01
INN (Alþjóðlegt nafn):
SUMATRIPTAN
Skammtar:
50MG
Lyfjaform:
TABLET
Samsetning:
SUMATRIPTAN (SUMATRIPTAN SUCCINATE) 50MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
30
Gerð lyfseðils:
Prescription
Lækningarsvæði:
SELECTIVE SEROTONIN AGONISTS
Vörulýsing:
Active ingredient group (AIG) number: 0123238002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2005-08-24
Vara einkenni
PRODUCT MONOGRAPH
PR
DOM-SUMATRIPTAN
Sumatriptan Tablets, USP
25 mg, 50 mg and 100 mg Sumatriptan (as Sumatriptan Succinate)
5-HT
1 RECEPTOR AGONIST
MIGRAINE THERAPY
DOMINION PHARMACAL
DATE OF PREPARATION:
6111 Royalmount Ave., Suite 100
March 21, 2016
Montreal, Quebec
H4P 2T4
CONTROL #:
193070
_Dom-SUMATRIPTAN Product Monograph _
_Page 2 of 39 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY
PRODUCT
INFORMATION
.................................................................................
3
INDICATIONS
AND
CLINICAL
USE
.......................................................................................
3
CONTRAINDICATIONS
............................................................................................................
4
WARNINGS
AND
PRECAUTIONS
...........................................................................................
4
ADVERSE
REACTIONS
..........................................................................................................
11
DRUG
INTERACTIONS
...........................................................................................................
14
DOSAGE
AND
ADMINISTRATION
.......................................................................................
14
OVERDOSAGE
.........................................................................................................................
16
ACTION
AND
CLINICAL
PHARMACOLOGY
.....................................................................
16
STORAGE
AND
STABILITY
...................................................................................................
18
DOSAGE
FORMS,
COMPOSITION
AND
PACKAGING ...................................................... 18
PART II: SCIENTIFIC INFORMATION
................................................................................
20
PHARMACEUTICAL
INFORMATION
..................................................................................
20
CLINICAL
TRIALS
.................
Lestu allt skjalið
